LTGO
Latigo Biotherapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-42/100
Last price
16.26
▼ 0.37 (2.22%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
16.63
Day high
16.85
Day low
16.06
Volume
544.51K
Market cap
$1.08B
P/E (TTM)
—
52W range
15.67 – 25.93
Trailing performance
Returnvs SPY
1W
-10.17%
-12.1%
1M
-29.43%
-30.6%
3M
—
-4.5%
6M
—
-18.2%
YTD
-10.90%
-25.2%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on LTGO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.30M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 10, 26 | SANOFI SA Beneficial Owner of more than 10% of a Class of Security |
— | 672.78K | — | Indirect |
| Aug 10, 26 | SEIDENBERG BETH C Director and Beneficial Owner of more than 10% of a Class of Security |
— | 12.70M | — | Indirect |
| Aug 10, 26 | 5AM VENTURES VI, L.P. Beneficial Owner of more than 10% of a Class of Security |
— | 7.33M | — | Indirect |
| Aug 10, 26 | TANANBAUM JAMES B Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 140.00K | $2.52M | Indirect |
| Aug 10, 26 | TANANBAUM JAMES B Director and Beneficial Owner of more than 10% of a Class of Security |
— | 9.04M | — | Indirect |
| Aug 10, 26 | FORESITE CAPITAL MANAGEMENT V, LLC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 140.00K | $2.52M | Indirect |
| Aug 10, 26 | FORESITE CAPITAL MANAGEMENT V, LLC. Beneficial Owner of more than 10% of a Class of Security |
— | 9.04M | — | Indirect |
| Aug 10, 26 | WESTLAKE BIOPARTNERS FUND I, L.P. Beneficial Owner of more than 10% of a Class of Security |
— | 12.70M | — | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
5AM VENTURES VI, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
FORESITE CAPITAL MANAGEMENT V, LLC. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
SANOFI SA |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
SEIDENBERG BETH C |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
TANANBAUM JAMES B |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
WESTLAKE BIOPARTNERS FUND I, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
Fundamentals
Market cap$1.08B
Enterprise value$1.34B
Revenue (TTM)—
Gross profit—
EBITDA$-112.16M
Net income$-111.14M
EPS (TTM)$-2.52
Free cash flow—
Total cash$55.00M
Total debt$31.25M
Book value / share$-279.37
Shares outstanding66.30M
Float21.74M
Short % of float—
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.78
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA-11.97
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity249.96
Current ratio1.15
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $0 | $0 | — |
| Operating revenue | $0 | $0 | — |
| Research & development | $99.53M | $56.78M | +75.3% |
| Selling, general & admin | $10.86M | $6.67M | +62.9% |
| Total operating expense | $110.39M | $63.45M | +74.0% |
| Operating income | -$110.39M | -$63.45M | -74.0% |
| Net interest income | $2.94M | $2.26M | +30.0% |
| Pre-tax income | -$109.17M | -$61.18M | -78.4% |
| Net income | -$109.17M | -$61.18M | -78.4% |
| Net income to common | -$109.17M | -$61.18M | -78.4% |
| Basic EPS | -2.48 | -1.39 | -78.4% |
| Diluted EPS | -2.48 | -1.39 | -78.4% |
| EBIT | -$110.39M | -$63.45M | -74.0% |
| EBITDA | -$110.14M | -$63.21M | -74.3% |
| Basic shares | 43.96M | 44.02M | -0.1% |
| Diluted shares | 43.96M | 44.02M | -0.1% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $69.44M | $17.92M | +287.5% |
| Cash & short-term investments | $69.44M | $17.92M | +287.5% |
| Total current assets | $73.83M | $21.16M | +248.8% |
| Property, plant & equipment | $1.07M | $1.41M | -24.0% |
| Total assets | $75.52M | $22.86M | +230.3% |
| Total current liabilities | $18.45M | $14.44M | +27.8% |
| Total debt | $690.00K | $851.00K | -18.9% |
| Total liabilities | $307.19M | $152.46M | +101.5% |
| Retained earnings | -$243.13M | -$133.96M | -81.5% |
| Shareholder equity | -$231.67M | -$129.60M | -78.8% |
| Working capital | $55.38M | $6.73M | +723.0% |
| Net tangible assets | -$231.67M | -$129.60M | -78.8% |
| Shares issued | 60.15M | 60.15M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | -$109.17M | -$61.18M | -78.4% |
| Depreciation & amortisation | $249.00K | $244.00K | +2.0% |
| Stock-based compensation | $6.72M | $2.77M | +142.8% |
| Change in working capital | $2.52M | $6.89M | -63.4% |
| Operating cash flow | -$97.56M | -$50.95M | -91.5% |
| Capital expenditure | -$136.00K | -$72.00K | -88.9% |
| Investing cash flow | -$136.00K | -$72.00K | -88.9% |
| Financing cash flow | $149.50M | $607.00K | +24,528.7% |
| Free cash flow | -$97.69M | -$51.03M | -91.5% |
| End cash position | $69.72M | $17.92M | +289.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $21.23M | $17.63M | $22.92M | $18.69M | +20.4% |
| Selling, general & admin | $4.58M | $5.80M | $2.82M | $2.82M | -21.0% |
| Total operating expense | $25.81M | $23.44M | $25.75M | $21.51M | +10.1% |
| Operating income | -$25.81M | -$23.44M | -$25.75M | -$21.51M | -10.1% |
| Net interest income | $13.00K | $474.00K | $868.00K | $517.00K | -97.3% |
| Pre-tax income | -$25.80M | -$22.96M | -$25.84M | -$20.95M | -12.4% |
| Net income | -$25.80M | -$22.96M | -$25.84M | -$20.95M | -12.4% |
| Net income to common | -$25.80M | -$22.96M | -$25.84M | -$20.95M | -12.4% |
| Basic EPS | -0.43 | -0.52 | -0.59 | -0.48 | +17.5% |
| Diluted EPS | -0.43 | -0.52 | -0.59 | -0.48 | +17.5% |
| EBIT | -$25.55M | -$23.44M | -$25.84M | -$21.51M | -9.0% |
| EBITDA | -$25.49M | -$23.39M | -$25.77M | -$21.45M | -9.0% |
| Basic shares | 60.15M | 44.02M | 44.02M | 44.02M | +36.6% |
| Diluted shares | 60.15M | 44.02M | 44.02M | 44.02M | +36.6% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $55.00M | $42.18M | +30.4% |
| Cash & short-term investments | $55.00M | $42.18M | +30.4% |
| Total current assets | $59.20M | $46.84M | +26.4% |
| Property, plant & equipment | $1.76M | $900.00K | +95.6% |
| Total assets | $64.76M | $50.58M | +28.0% |
| Total current liabilities | $51.58M | $14.49M | +255.9% |
| Current debt | $29.90M | — | — |
| Total debt | $31.25M | $554.00K | +5,540.8% |
| Total liabilities | $340.84M | $303.16M | +12.4% |
| Retained earnings | -$291.89M | -$266.09M | -9.7% |
| Shareholder equity | -$276.08M | -$252.58M | -9.3% |
| Working capital | $7.62M | $32.35M | -76.4% |
| Net tangible assets | -$276.08M | -$252.58M | -9.3% |
| Shares issued | 60.15M | 60.15M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$25.80M | -$22.96M | -$25.84M | -$20.95M | -12.4% |
| Depreciation & amortisation | $52.00K | $47.00K | $66.00K | $67.00K | +10.6% |
| Stock-based compensation | $2.14M | $1.98M | $1.68M | $1.48M | +8.3% |
| Change in working capital | $1.89M | -$6.26M | $1.51M | -$1.78M | +130.2% |
| Operating cash flow | -$21.28M | -$27.07M | -$21.56M | -$21.16M | +21.4% |
| Capital expenditure | — | — | -$33.00K | -$102.00K | — |
| Investing cash flow | -$110.00K | $0 | -$33.00K | -$102.00K | — |
| Financing cash flow | $34.18M | -$230.00K | -$1.00K | $99.43M | +14,960.4% |
| Free cash flow | -$21.39M | -$27.07M | -$21.59M | -$21.26M | +21.0% |
| End cash position | $55.21M | $42.42M | $74.50M | $96.09M | +30.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.67 | -27.59 | -4,048.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.67 | 2 | $0 | — |
| Next quarter | -0.85 | 2 | $0 | — |
| Current year | -3.01 | 3 | $0 | — |
| Next year | -2.32 | 4 | $0 | 0.0% |
Analyst targets & ownership
Mean target$52.25
High target$73.00
Low target$36.00
Implied upside221.34%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders4.98%
Held by institutions79.04%
Institutions holding12
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
17.26
-5.82% from price
SMA 20
19.81
-17.93% from price
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
17.89
-9.10% from price
EMA 26
19.28
-15.66% from price
EMA 50
—
—
RSI (14)
35.1
Neutral
MACD (12,26,9)
-1.39
Hist -0.52
ATR (14)
1.59
9.77% of price
Realised vol 30D
72.2%
Annualised
Bollinger upper
25.30
20, 2σ
Bollinger lower
14.33
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
72.2%
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
-36.4%
Peak to trough
Max drawdown 5Y
-36.4%
Peak to trough
ATR 14
1.59
9.77% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
449.96K
Prior 134.47K
Change vs prior
+234.6%
Shorts adding
% of float
—
—
% of shares out
0.68%
Against total outstanding
Days to cover
2.3
Liquid
Float
21.74M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 1, 26 | Leerink Partners | INITIATED | — | Outperform |
| Sep 1, 26 | Jefferies | INITIATED | — | Buy |
| Sep 1, 26 | Guggenheim | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-09-03
Offering Registrations
S-8 · 2026-08-10
Offering Registrations
S-1MEF · 2026-08-06
Offering Registrations
S-1/A · 2026-08-04
Offering Registrations
S-1/A · 2026-08-03
Offering Registrations
S-1 · 2026-07-17
Offering Registrations
DRS/A · 2026-06-05
Offering Registrations
DRS/A · 2026-05-18
Headlines
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
TipRanks · 29d ago
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · 34d ago
Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued
Simply Wall St. · 58d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.